TRex Bio (NASDAQ:TRXB) Now Covered by Analysts at Cantor Fitzgerald

Cantor Fitzgerald started coverage on shares of TRex Bio (NASDAQ:TRXB) in a research report issued to clients and investors on Tuesday, Briefing.com reports. The brokerage set an “overweight” rating on the stock.

A number of other brokerages have also recently weighed in on TRXB. Stifel Nicolaus started coverage on TRex Bio in a research report on Tuesday. They set a “buy” rating and a $39.00 price target on the stock. JPMorgan Chase & Co. started coverage on TRex Bio in a research report on Tuesday. They set an “overweight” rating and a $20.00 price objective for the company. Finally, Wedbush assumed coverage on TRex Bio in a research note on Monday. They set an “outperform” rating and a $30.00 price objective for the company. Four research analysts have rated the stock with a Buy rating. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $29.67.

TRex Bio Stock Down 0.7%

Shares of TRXB stock opened at $13.64 on Tuesday. TRex Bio has a 52 week low of $13.10 and a 52 week high of $16.56.

Insider Transactions at TRex Bio

In other TRex Bio news, major shareholder Alexandria Venture Investments acquired 178,571 shares of the firm’s stock in a transaction that occurred on Tuesday, October 13th. The stock was acquired at an average cost of $14.00 per share, with a total value of $2,499,994.00. Following the acquisition, the insider directly owned 1,346,501 shares of the company’s stock, valued at $18,851,014. This represents a 15.29% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

TRex Bio Company Profile

We are a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio was built on a pivotal scientific insight: that regulatory T cells (“Tregs”) in human tissue are not merely passive suppressors of inflammation, but active orchestrators of tissue immune homeostasis and repair.